A Phase 3, Randomized Study of Margetuximab Plus Chemotherapy vs Trastuzumab Plus Chemotherapy in the Treatment of Patients with HER2+ Metastatic Breast Cancer Who Have Received Two Prior Anti-HER2 Therapies and Require Systemic Treatment

Dr. Linda Vahdat is seeking men and women with HER2+ metastatic breast cancer to participate in a research study.

The purpose of this study is to evaluate the effectiveness of margetuximab in combination with standard of care chemotherapies in the setting of patients with metastatic HER2+ breast cancer who have received prior treatment with trastuzumab, pertuzumab, and adotrastuzumab.

To see learn more and see if you qualify to participate [go]

Leave a Comment

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s